Sleep apnea and its outcomes in people with pulmonary hypertension
Studies sleep apnea with an overnight sleep test in adults with pulmonary hypertension.
Plain-language title generated from the registry record
Registry title: Prevalence, Phenotypes, Predictors and Prognostic Implication of Obstructive Sleep Apnea in Pulmonary Hypertension
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose pulmonary hypertension was confirmed by right heart catheterization. It studies how sleep apnea affects their health over time.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Pulmonary hypertension diagnosed by right heart catheterization
- Earlier treatment
- Cannot have had treatment for sleep-disordered breathing before
Main reasons for not taking part
- Pregnancy
- Central sleep apnea
- Previous treatment for sleep-disordered breathing
- Sleep data unavailable or incomplete
- Needing extra oxygen at night
Read by machine on 12 November 2026.
Where in China
- Center for Respiratory and Pulmonary Vascular Diseases, Fuwai hospital, CAMS & PUMCBeijing, ChinaContact: Zhihong Liu, MD,PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Chinese Pulmonary Vascular Disease Research Group
- Trial code
- NCT05595200
- Record updated
- 26 October 2026
- Original description
The investigators propose a prospective, observational study to determine the impact of OSA and associated physiological parameters on clinical outcomes in patients with pulmonary hypertension. The prevalence, phenotypes, and predictors of OSA in the setting of pulmonary hypertension will also be investigated. Adult patients diagnosed with pulmonary hypertension by right heart catheterization are eligible. Recruited patients will undergo an overnight cardiorespiratory study using a Level III portable device before hospital discharge. The cardiorespiratory tracings during sleep will be analyzed and audited by a certified sleep physician. The patients will be divided into two groups based on the apnea-hypopnea index (AHI): OSA (AHI ≥ 5) and non-OSA (AHI<5) groups. Hypoxemic parameters such as time percentage spent with oxygen saturation below 90% and nadir oxygen saturation were all collected. Baseline clinical characteristics, such as the Epworth sleepiness scales, were also obtained. The primary endpoint of this study was clinical worsening (CW), defined as the composite event of a reduction in exercise capacity, worsening in World Health Organization functional class, non-elective hospitalization for pulmonary hypertension, or all-cause mortality. Secondary endpoints include individual outcomes of clinical worsening and all-cause mortality.Read full original descriptionShow less
Prevalence, Phenotypes, Predictors and Prognostic Implication of Obstructive Sleep Apnea in Pulmonary Hypertension
The investigators propose a prospective, observational study to determine the impact of OSA and associated physiological parameters on clinical outcomes in patients with pulmonary hypertension. The prevalence, phenotypes, and predictors of OSA in the setting of pulmonary hypertension will also be investigated. Adult patients diagnosed with pulmonary hypertension by right heart catheterization are eligible. Recruited patients will undergo an overnight cardiorespiratory study using a Level III portable device before hospital discharge. The cardiorespiratory tracings during sleep will be analyzed and audited by a certified sleep physician. The patients will be divided into two groups based on the apnea-hypopnea index (AHI): OSA (AHI ≥ 5) and non-OSA (AHI<5) groups. Hypoxemic parameters such as time percentage spent with oxygen saturation below 90% and nadir oxygen saturation were all collected. Baseline clinical characteristics, such as the Epworth sleepiness scales, were also obtained. The primary endpoint of this study was clinical worsening (CW), defined as the composite event of a reduction in exercise capacity, worsening in World Health Organization functional class, non-elective hospitalization for pulmonary hypertension, or all-cause mortality. Secondary endpoints include individual outcomes of clinical worsening and all-cause mortality.
Inclusion: Aged ≥18 years old; Diagnosed with pulmonary hypertension by right heart catheterization.
Exclusion: Previous treatment for sleep-disordered breathing; Pregnancy; Central sleep apnea; Unavailable or incomplete sleep data; Requiring nocturnal oxygen supplementation.